ONX-0914,alsoknownasPR-957,isapotentinhibitoroftheimmunoproteasomewithminimalcross-reactivityfortheconstitutiveproteasome.ONX-0914selectivelyinhibitslow-molecularmasspolypeptide-7(LMP7),thesubunitspecificfortheimmunoproteasomethatcatalyzesthechymotyrpsion-likeactivity,withanIC
50<100=""nm.=""cell=""culture=""and=""animal=""studies=""have=""shown=""that=""onx-0914=""blocks=""the=""production=""of=""proinflammatory=""cytokines=""including=""interleukin-6=""and=""17,=""indicating=""that=""it=""has=""potential=""uses=""in=""the=""treatment=""of=""some=""autoimmune=""diseases=""such=""as=""rheumatoid=""arthritis,=""inflammatory=""bowel=""disease=""and=""lupus.="">
Dose:0.1-0.5μMforinvitroorcellcoutureassays;intravenousorsubcutaneousadmi
NISTrationat2-10mg/Kgdailyfor5-7daysforanimalstudies.
ProductName: | ONX-0914(PR-957) |
---|
AlsoKnownAs: | ONX0914;ONX0914;ONX-0914;PR-957;CAS#:960374-59-8 |
---|
CatalogNo.: | F1410 |
---|
Size: | 5mg |
---|
MolecularWeight: | 580.7Da |
---|
Species: | N/A |
---|
Source: | Synthetic |
---|
Stock: | Powder |
---|
Concentration: | N/A |
---|
QualityAssurance: | >98%byHPLCandNMR |
---|
Storage: | EligIBLeforroomtemperatureshipping.Storeat-80°Cuponreceiving;avoidmultiplefreeze-thawcyclesafterdissolvinginDMSO. |
---|
PDFDataSheet: | PDFDatasheet |
---|
NCBIRefSeq: | N/A |
---|
Image(s): | No |
---|
ShippingMethod: | Roomtemperatureshipping |
---|
References: | 1.MuchamuelT,etal.(2009)NatMed.15(7):781-7. 2.BaslerM,etal.(2010)JImmunol.185(1):634-41.3.KalimKW,etal.(2012)JImmunol.189(8):4182-93. |
---|
Details
ONX-0914,alsoknownasPR-957,isapotentinhibitoroftheimmunoproteasomewithminimalcross-reactivityfortheconstitutiveproteasome.ONX-0914selectivelyinhibitslow-molecularmasspolypeptide-7(LMP7),thesubunitspecificfortheimmunoproteasomethatcatalyzesthechymotyrpsion-likeactivity,withanIC50<100=""nm.=""cell=""culture=""and=""animal=""studies=""have=""shown=""that=""onx-0914=""blocks=""the=""production=""of=""proinflammatory=""cytokines=""including=""interleukin-6=""and=""17,=""indicating=""that=""it=""has=""potential=""uses=""in=""the=""treatment=""of=""some=""autoimmune=""diseases=""such=""as=""rheumatoid=""arthritis,=""inflammatory=""bowel=""disease=""and=""lupus.="">
Dose:0.1-0.5μMforinvitroorcellcoutureassays;intravenousorsubcutaneousadministrationat2-10mg/Kgdailyfor5-7daysforanimalstudies.
泛素-蛋白酶体生物技术有限公司(UBPBio),LLC是一家私有公司,由科学家和投资人于2011年成立。UBPBio致力于为学术界和工业界提供高质量的试剂,以加快对泛素-蛋白酶体系统及相关途径的发现。 。目前,我们的产品线包括16个类别,提供350多种产品。如果您在泛素领域需要特殊试剂,请与我们联系,我们将竭诚为您服务。